Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SCN4A | P35499 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533171 | 0.84 | NPC1 (0.31) | NPC1GMNNUSP2LMNATP53 | |
| SCHEMBL533345 | 0.83 | NPC1 (0.46) | KIF11NPC1GMNNUSP2LMNA | |
| SCHEMBL533031 | 0.80 | CYP1A2 (0.45) | NPC1CYP1A2CYP3A4RAB9ASMN1; SMN2 | |
| SCHEMBL533036 | 0.76 | KMT2A (0.46) | NPC1LMNATP53CYP1A2CYP3A4 | |
| SCHEMBL533913 | 0.76 | ALDH1A1 (0.39) | ABL1LMNATP53CYP3A4GAA | |
| SCHEMBL533424 | 0.76 | ALOX15 (0.34) | ABL1LMNACYP3A4CYP2C9PKM | |
| SCHEMBL3820319 | 0.74 | KIF11 (0.47) | KIF11ABL1SRD5A1NPC1CYP1A2 | |
| SCHEMBL533355 | 0.72 | — | — | |
| SCHEMBL533531 | 0.72 | XDH (0.40) | ABL1NPC1LMNACYP2C9RAB9A | |
| SCHEMBL3794893 | 0.71 | MRGPRX4 (0.40) | KIF11ABL1NPC1GMNNUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KIF11 3619/4885ABL1 2803/4885SRD5A1 2044/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KIF11 3705/4885ABL1 3139/4885SRD5A1 2319/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | KIF11 2467/4885ABL1 2982/4885SRD5A1 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.